The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point. In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV

• https://twitter.com/i/web/status/1751341200462795097
• https://twitter.com/uptoTate/status/1751341200462795097/photo/1
• https://twitter.com/uptoTate/status/1751341200462795097/photo/1

@RheumNow #RNL2024 Winthrop: JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R

• https://twitter.com/ericdeinmd/status/1751340479893975188/photo/1
• https://twitter.com/ericdeinmd/status/1751340479893975188/photo/1

So why should you consider JAKi? Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety. #RNL2024 @RheumNow https://t.co/BgFjhb18Ad

• https://twitter.com/uptoTate/status/1751333860707615133/photo/1

Random effect in ACR20 responses in male versus females in PsA. No sex differences in ACR20 responses in patients on JAK/TYK2i . @lihi_eder #RNL2024 @RheumNow https://t.co/fgEORm0nKc

• https://twitter.com/NoufAhmedAlham2/status/1751326271009603994/photo/1

Sex/Gender disparities in rheumatology. @lihi_eder #RNL2024 @RheumNow https://t.co/PB7zPYJHd0

• https://twitter.com/NoufAhmedAlham2/status/1751326448571351429/photo/1

A word on Explicit/ Implicit Bias . Amazing talk and very insightful. @lihi_eder #RNL2024 @RheumNow https://t.co/SGmk5wa9nP

• https://twitter.com/NoufAhmedAlham2/status/1751326897575784647/photo/1

JAKi toxicities of interest: - Zoster - Safety: VTE, MACE, Malignancies - Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias. @JointMD #RNL2024 @rheumnow https://t.co/u72yz8uLYB

• https://twitter.com/uptoTate/status/1751332031470961054/photo/1

@JointMD reviews the pros and cons of JAKi at #RNL2024 @RheumNow https://t.co/z9CSvP5BAZ

• https://twitter.com/uptoTate/status/1751328406912799112/photo/1
• https://twitter.com/uptoTate/status/1751328406912799112/photo/1

More evidence to support role of Tyk2 in management of skin psoriasis. Dr.April Armstrong #RNL2024 @RheumNow https://t.co/9vuuhJMj36

• https://twitter.com/NoufAhmedAlham2/status/1751324417777389949/photo/1
• https://twitter.com/NoufAhmedAlham2/status/1751324417777389949/photo/1

Amazing talk by @lihi_eder on sex differences in PsA. #RNL2024 @RheumNow https://t.co/PW5fYLYmu5

• https://twitter.com/NoufAhmedAlham2/status/1751324759025934635/photo/1
• https://twitter.com/NoufAhmedAlham2/status/1751324759025934635/photo/1

Crossed out all therapies that doesn’t work for skin psoriasis. For some reason, i thought that JAKi s worked for skin psoriasis. Thanks to Dr.Armstrong for clarifying. #RNL2024 @RheumNow https://t.co/f71qmHGLwm

• https://twitter.com/NoufAhmedAlham2/status/1751324051568529760/photo/1

FDA-approved biologics for skin psoriasis by April Armstrong , its always nice to hear from Derm colleagues. #RNL2024 @RheumNow https://t.co/vTLpOim8Ct

• https://twitter.com/NoufAhmedAlham2/status/1751323269578252630/photo/1

Impact of obesity on PsA @AlexisOgdie Weight loss works in PsA: 5 to 10% weight loss lead to OR: 3.7 MDA responses > 10% of body weight lead even higher odds ( 6.67). #RNL2024 @RheumNow https://t.co/73O0I7uZF4

• https://twitter.com/NoufAhmedAlham2/status/1751322836596048361/photo/1
• https://twitter.com/NoufAhmedAlham2/status/1751322836596048361/photo/1

Sever psoriatic arthritis / psoriasis by @AlexisOgdie #RNL2024 @RheumNow https://t.co/KbN7mnHTSd

• https://twitter.com/NoufAhmedAlham2/status/1751321157322645626/photo/1

Treating dactylitis and enthesitis: this is a sign of aggressive disease. Dr. @AlexisOgdie will treat with high dose NSAIDS and get patients on biologics quickly. #RNL2024 @rheumnow